Quality | 2017.06.14
Janssen Presents Long Term Phase 3 Efficacy and Safety Data of Sirukumab in Rheumatoid Arthritis Patients Who had an Inadequate Response and/or Who Were Intolerant to Anti-TNFs
MADRID, June 14, 2017 /PRNewswire/ -- Sirukumab Phase 3 Data Presented at the Annual European Congress of Rheumatology (EULAR) 2017 also Show Significant Improvement in Quality of Life Measures Janssen-Cilag International NV (Janssen) today announced long-term results from...
For more information, please visit
http://www.prnewswire.com/news-releases/[...]nt-to-anti-tnfs-628433933.html
